Multispecific Antibody Targeting CD79b and CD22 for Autoimmune Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases often fail to effectively modulate B cell activation, leading to persistent autoimmune responses and tissue damage.
Innovation Solution
Development of multispecific antibodies that simultaneously bind to CD79B and CD22, which are key proteins involved in B cell activation, to modulate B cell function and reduce autoimmune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for autoimmune diseases are used, then treatment simplicity is maintained, but B cell activation modulation effectiveness is insufficient
Solution Approach 1:
The patent combines two antigen-binding arms into a single multispecific antibody molecule: one arm targets CD79B on B cells while the other arm targets CD22 on regulatory T cells. This merging approach allows simultaneous modulation of both B cell activation and regulatory T cell function, thereby improving treatment effectiveness for autoimmune diseases without requiring multiple separate therapies
Solution Approach 2:
The multispecific antibody performs multiple therapeutic functions simultaneously: it blocks B cell receptor signaling through CD79B binding, enhances regulatory T cell-mediated suppression through CD22 binding, and modulates both effector and regulatory immune pathways. This multi-functionality addresses the insufficiency of current single-target treatments while maintaining a single-administration format
2Reliability
If multisspecific antibodies binding both CD79B and CD22 are developed, then B cell activation modulation is improved, but antibody structural complexity increases
Solution Approach 1:
The antibody is segmented into two distinct antigen-binding arms with different specificities: one arm contains variable regions (VH1/VL1) specific for CD79B, while the other arm contains variable regions (VH2/VL2) specific for CD22. Each arm can be independently designed and optimized, allowing complex functionality to be achieved through modular segmentation rather than monolithic design
Solution Approach 2:
The constant regions of the antibody (CH1, CH2, CH3 domains) serve as intermediary structures that connect and stabilize the two different variable regions. These intermediary constant domains provide a standardized framework that simplifies the overall structure by using repeated modular units, rather than requiring entirely unique structural elements for each antigen-binding function
3Reliability
If multisspecific antibodies are used to inhibit B cell proliferation, then autoantibody production is reduced, but treatment specificity requirements increase
Solution Approach 1:
Each antigen-binding arm is optimized with locally specific variable regions tailored to its target: the CD79B-binding arm has variable regions (VH1/VL1) with complementarity determining regions specifically adapted for CD79B epitopes, while the CD22-binding arm has variable regions (VH2/VL2) optimized for CD22 recognition. This local optimization ensures high binding specificity at each interaction site, preventing off-target effects while achieving the desired therapeutic outcome of reduced autoantibody production
Data Source
AI summary
Provided herein are multispecific antibodies, that bind to CD79b and CD22, polynucleotides encoding them, vectors, host cells, methods of making and using them.